Skip to content

The Efficacy of Magnetic Stimulation in Patients with Major Depressive Disorder

The Efficacy of Repetitive Transcranial Magnetic Stimulation in Patients with Major Depressive Disorder Resistant to First-line Pharmaceutical Therapy: A Double-blinded Randomized Clinical Trial

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20190612043877N1
Enrollment
60
Registered
2022-06-13
Start date
2022-06-02
Completion date
Unknown
Last updated
2022-06-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major Depressive Disorder Resistant to First-line Pharmaceutical Therapy. F33

Interventions

Intervention 1: • The rTMS protocol is performed by a MagVenture device (Denmark) with an 8-shaped coil equipped with a cooling system. Before each rTMS session, participants' motor threshold (MT) is

Sponsors

Qazvin University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria were the age of 18 to 70 years Primary diagnosis of MDD by a psychiatrist based on the criteria of the Diagnostic and Statistical Manual of Mental Disorders version V (DSM-V). the patients whose MDD was approved by a specialist according to MDD criteria and who had received and failed to respond to an episode of treatment (for at least six weeks) with effective tolerated doses of antidepressants were included in the study. The patients should have received the same medication from six weeks to the onset of the study and continued taking the drug during the study. Exclusion criteria comprised the presence of underlying diseases History of rTMS treatment due to any disorder History of seizures or neurosurgery, Having a pacemaker Pregnancy Being diagnosed with a high risk of suicide, substance abuse, and unwillingness to participate in the study.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Depression symptoms. Timepoint: At baseline (before intervention) and the second and fourth weeks after intervention. Method of measurement: The Hamilton Rating Scale.

Secondary

MeasureTime frame
Severity of the disease. Timepoint: At baseline (before intervention) and the second and fourth weeks after intervention. Method of measurement: Clinical Global Impression–Severity scale (CGI-S).;Illness Perception. Timepoint: At baseline (before intervention) and the second and fourth weeks after intervention. Method of measurement: the Brief Illness Perception Questionnaire (Brief IPQ).

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAlireza Haji Seyed Javadi

Qazvin University of Medical Sciences

ahsjavadi@qums.ac.ir+98 28 3355 5054

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 6, 2026